Evaluation of Original and Modified APC-Resistance Tests in Unselected Outpatients with Clinically Suspected Thrombosis and in Healthy Controls

Peter J Svensson; Bengt Zöller; Björn Dahlbäck

doi:10.1055/s-0038-1655964

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1997; 77(02): 332-335
DOI: 10.1055/s-0038-1655964

Original Article

Schattauer GmbH Stuttgart

Evaluation of Original and Modified APC-Resistance Tests in Unselected Outpatients with Clinically Suspected Thrombosis and in Healthy Controls

Peter J Svensson

¹Department for Coagulation Disorders, University Hospital, Malmö, Sweden

,

Bengt Zöller

²Department of Clinical Chemistry, University of Lund, The Wallenberg Laboratory, University Hospital, Malmö, Sweden

,

Björn Dahlbäck

²Department of Clinical Chemistry, University of Lund, The Wallenberg Laboratory, University Hospital, Malmö, Sweden

› Author Affiliations

Abstract

PDF Download

Summary

APC-resistance is the most common hereditary condition associated with venous thrombosis. It is in a majority of cases due to a single point mutation in the factor V gene (FVR506Q). Currently used functional APC-resistance tests have 85-90% sensitivity and specificity for the FVR506Q mutation. A modified test which includes predilution of patient plasma in factor V depleted plasma has increased the sensitivity and specificity for the factor V mutation. However, neither the original nor the modified APC-resistance test have been evaluated in patients with acute thrombotic events. We have therefore used the original and the modified APC-resistance tests in 220 patients with clinically suspected acute deep venous thrombosis and in 278 healthy controls. The FVR506Q mutation was determined in all patients. The patients were classified as either DVT (deep venous thrombosis)-negative or DVT-positive depending on the outcome of contrast phlebography. In individuals with normal factor V genotype, the original APC-resistance test gave significantly lower APC-ratio values both in DVT-positive and DVT-negative patients than in healthy controls. The specificity of the original APC-resistance test for the FVR506Q mutation in controls and in DVT-negative and DVT-positive patients were 85%, 54% and 28%, respectively, when a cut off APC-ratio of 3.2 which insured 100% sensitivity was used. Using the modified APC-resistance test, essentially no difference in APC-ratios between patients with normal factor V genotype and healthy controls with normal factor V genotype was observed. The modified APC-resistance test had a specificity for the FVR506Q mutation of 98.8% at an APC-ratio cut off of 2.1 which ensured 100% sensitivity. The original APC-resistance test gave lower APC-ratios in women than in men and in patients with acute thrombosis as compared to controls. In conclusion, the modified APC-resistance test is highly sensitive and specific for the FVR506Q mutation. This test can be used in clinical practice as an easy to perform screening test for the FVR506Q allele. Moreover, the test performs equally well in patients with acute suspected venous thrombosis as in healthy controls.

PDF (315 kb)

References

References
1 Dahlbӓck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C:Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
2 Svensson PJ, Dahlbӓck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-521
3 Koster T, Rosendaal FR, de RondeF, Briёt E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C:Leiden thrombophilia study. Lancet 1993; 342: 1503-1506
4 Griffin JH, Evatt BL, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989-1993
5 Halbmayer WM, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994; 5: 51-57
6 Faioni EM, Franchi F, Asti D, Sacchi E, Bemardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families:Interference in a protein S functional assay. Thromb Haemost 1993; 70: 1067-1071
7 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917
8 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der VeldenPA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
9 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt BL. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1362-1363
10 Voorberg J, Roelse J, Koopman R, Büller H, Berends F, Ten CateJW, Mertens K, van MourikJA. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994; 343: 1535-1536
11 Zöller B, Dahlbӓck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538
12 Dahlbӓck B. Resistance to activated protein C, the Arg506 to Gin mutation in the factor V gene, and venous thrombosis. Functional tests and DNA based assays, pros and cons. Thromb Haemost 1995; 73: 739-742
13 Zöller B, Svensson PJ, He X, Dahlbӓck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inher-ited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524
14 Engel H, Zwang L, van VlietHHDM, Michiels JJ, Stibbe J, Lindemans J. Phenotyping and genotyping of coagulation factor V Leiden. Thromb Haemost 1996; 75: 267-269
15 Gouault-Heilmann M, Leroy-Matheron C. Factor V Leiden-dependent APC resistance:improved sensitivity and specificity of the APC resistance test by plasma dilution in factor V-depleted plasma. Thromb Res 1996; 82: 281-283
16 Dahlbӓck B, Hillarp A, Rosen S, Zöller B. Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. Ann Hematol 1996; 72: 166-176
17 de RondeH, Bertina RM. Laboratory diagnosis of APC-resistance:a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-886
18 Rosén S, Johansson K, Lindberg K, Dahlbӓck B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost 1994; 72: 255-260
19 Trossaёrt M, Conard J, Horellou MH, Samama MM. Influence of storage conditions on activated protein C resistance assay. Thromb Haemost 1995; 73: 163
20 Freyburger G, Bilhou-Nabera C, Dief S, Javorschi S, Labrouche S, Lerebeller MJ, Boisseau MR. Technical and biological conditions influencing the functional APC resistance test. Thromb Haemost 1996; 75: 4460-4465
21 Henkens CMA, Bom VJJ, Seinen AJ, van der MeerJ. Sensitivity to activated protein C;influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-404
22 Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CRM. Development of resistance to activated protein c during pregnancy. Br J Haematol 1995; 90: 725-727
23 Halbmayer WM, Haushofer A, Schön R, Fischer M. Influence of lupus anticoagulant on a commercial available kit for APC-resistance. Thromb Haemost 1994; 72: 643-651
24 Jorquera JI, Montoro JM, Fernandez MA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163
25 Trossaёrt M, Coηard J, Horellou MH, Samama MM, Ireland H, Bayston TA, Lane DA. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709
26 Tosetto A, Rodeghiero F. Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost 1995; 73: 732-733
27 Denson KWE, Reed SV, Haddon RME. The modified APC resistance test. Thromb Haemost 1995; 74: 995
28 Trossaёrt M, Conard J, Horellou MH, Elalamy I, Samama M. The modifed APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulation. Thromb Haemost 1996; 75: 521-522
29 Cadroy Y, Sié P, Alhenc GelasM, Aiach M. Evaluation of APC resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants. Thromb Haemost 1995; 73: 734-735
30 Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2802
31 Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter Ch. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996; 75: 229-232
32 Henkens CM, Bom VJJ, van der MeerJ. Lowered APC-sensitivity ratio related to increased factor VUI-clotting activity. Thromb Haemost 1995; 74: 1198-1199
33 Koster T, Blann AD, Briёt E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155
34 Svensson PJ, Zöller B, Mattiasson J, Dahlbӓck B. The factor VR506 Q mutation causing APC resistance is highly prevalent among unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med. 1997 (in press)